SUMMARY Combined treatment with cimetidine 1 g daily and cisapride 40 mg daily in patients with endoscopically diagnosed severe reflux oesophagitis was compared with single drug therapy (cimetidine and placebo). At the end of the six to 12 weeks treatment, 11 (46%) of the 24 patients under single drug therapy were endoscopically healed and three were improved. In contrast, 16 (70%) of the 23 patients under combined therapy were healed and all of the remainder were improved (p= 0.25). The severity of diurnal and nocturnal heartburn, decreased significantly more (p<005) on cimetidine+cisapride than on cimetidine+placebo. The combined treatment was well tolerated. These results suggest that combined therapy with cisapride and cimetidine may be useful in patients with severe reflux oesophagitis.
SUMMARY Combined treatment with cimetidine 1 g daily and cisapride 40 mg daily in patients with endoscopically diagnosed severe reflux oesophagitis was compared with single drug therapy (cimetidine and placebo). At the end of the six to 12 weeks treatment, 11 (46%) of the 24 patients under single drug therapy were endoscopically healed and three were improved. In contrast, 16 (70%) of the 23 patients under combined therapy were healed and all of the remainder were improved (p= 0.25). The severity of diurnal and nocturnal heartburn, decreased significantly more (p<005) on cimetidine+cisapride than on cimetidine+placebo. The combined treatment was well tolerated. These results suggest that combined therapy with cisapride and cimetidine may be useful in patients with severe reflux oesophagitis.
Major factors in the pathogenesis of gastrooesophageal reflux disease include the competence of the lower oesophageal sphincter, efficacy of the oesophageal clearance function, irritant effect of refluxed material, and resistance of the oesophageal mucosa. 1-3 A stepwise strategy has been suggested for the treatment of this chronic digestive disorder.45 Elevation of the head of the bed, dietary modifications, and the use of antacids seem useful to the majority of patients with mild or intermittent symptoms. Some patients fail to respond to this socalled 'phase-I' therapy, however, and more active pharmacological agents ('phase-2' treatment) are required in order to increase the lower oesophageal sphincter pressure, amplitude of peristaltism, and rate of gastric emptying as well as reduce gastric acid secretion.
Cisapride is a newly developed digestive prokinetic drug' which increases the lower oesophageal sphincter pressure and enhances oesophageal acid clearance, thus preventing excessive regurgitation and prolonged exposure of the oesophageal mucosa to refluxed material. Cisapride also promotes gastric emptying of both solids and liquids7 and reduces duodenogastric bile reflux.8 Although cisapride has indirect cholinomimetic effects, it does not affect gastric acid output.' When compared with placebo, the drug has been shown to be effective in the treatment of gastro-oesophageal reflux with regard to symptomatic relief and healing of mucosal lesions." ' The efficacy of H2-blockers in peptic oesophagitis is well established but the benefit of combined therapy using cimetidine and prokinetic drugs such as metoclopramide is still a matter of debate; conflicting results have been reported." 12 This prompted us to evaluate the possible benefit of combined therapy with cisapride+cimetidine in patients with severe reflux oesophagitis. Our primary aim was to assess the healing rate of endoscopic lesions after single drug therapy (cimetidine+placebo) and after combined therapy (cimetidine+cisapride); our secondary aim was to study symptom relief during both 1 Severity ofoesophageal erosions at the start, aftersix weeks, and at the end oftreatment (week 6 or 12). end of treatment, 16 patients in the CIS+CIM group were healed, and the remaining seven were improved; in the PLAC+CIM group, 11 patients were healed and three improved. In 10 patients, all in the PLAC+CIM group, the aspect of the mucosa was not substantially modified as compared with the pretreatment condition; the intergroup difference was significant (p=0.025).
The changes in erosion ratings are shown in Figure  1 . All patients had erosions at the beginning of the trial. At the end of treatment (week 6 or 12), 16 patients in the CIS+CIM group had no erosions versus 11 in the PLAC+CIM group; in the latter group, six patients still had large lesions (score 3).
The changes in severity of ulceration, friability, and exudation are summarised in Table 3 . Presence Table 3 Changes in severity ratingsfor endoscopicsigns of oesophagitis . Figure 2 . After six weeks and at the end of treatment, the symptom severity in both groups was significantly (p<0.01) lower than at the start. As compared with placebo, however, cisapride significantly enhanced the effect of cimetidine (Fig. 2) .
The global evaluation of treatment at its end (weeks 6 or 12) is presented in Figure 3 . The investigators rated the result excellent or good in 87% of the patients in the CIS+CIM group, against 64% of the patients in the PLAC+CIM group (p<0 05). The assessment by the patients yielded similar results in favour of combined therapy.
DIARIES
Fifteen patients in the CIS+CIM group and 13 in the PLAC+CIM group completed their diaries in the first six week treatment period; nine and 10 patients, respectively, did so during weeks 6 to 12. Ridit analysis of the changes in the cluster of reflux symptoms showed a significant (p>0-001) improvement in both groups. Maalox® consumption was lower in the CIS+CIM group than in the PLAC+ CIM group: the mean weekly number of tablets .c
Cd + 4) .L E Fig. 3 Global clinical evaluation by investigator and patients at the end oftreatment (week 6 or 12). taken was, respectively, 3 7 and 11.9 (weeks 1-3; each week pe005), 2.8 and 8 9 (weeks 4-6; pc0()03); 4-6 and 6*5 (weeks 7-9; NS), 3*9 and 5*4
(weeks 10-12; NS). Analysis of variance done on the overall ridits, combining Maalox® consumption and frequency of daytime and night time heartburn and regurgitation, indicated that a highly significant part of the variance could be explained by the model used. This model takes into account the medication groups, duration of treatment, patients allocated to the medication groups, and interaction between medication groups and duration of treatment (Table 4) . Medication and patients were highly significant sources of variation (13.6% and 59% phagitis."' The combined therapeutic effect of cimetidine (300 mg qid) and metoclopramide (10 mg qid) was compared with that of cimetidine and placebo. A significant benefit in healing of mucosal lesions and a reduction in symptoms was observed in refractory patients receiving combined therapy. The high incidence of side effects with metoclopramide may have biased the study, however,5 as the investigators might have been aware of which patients were taking metoclopramide rather than placebo.
The results of the present trial indicate that patients with erosive oesophagitis showed better symptomatic and endoscopic response to cisapride+ cimetidine therapy than to cimetidine administration alone. The overall endoscopic healing rates were 70% and 46%, and marked improvement was noted in another 30% and 13% of the patient in the CIS+CIM and PLAC+CIM groups, respectively. The superiority of the combined therapy became particularly evident between the sixth and 12th week of treatment in patients who failed to fully respond during the first six week period. These results differ from those obtained by Wienbeck' who failed to show any significant difference between ranitidine+ cisapride and ranitidine alone. This apparent difference, however, may be because of either the lower dosage of cisapride used in the latter study (20 mg instead of 40 mg in our trial) and/or the more pronounced efficacy of ranitidine in controlling acid reflux (compared with cimetidine) as suggested by our previous findings with prolonged oesophageal pH measurements.'
In the present study cisapride was well tolerated and no serious side effects were observed. This finding contrasts with the poor tolerance of metoclopramide generally reported,4 at least at the high doses required for the treatment of reflux oesophagitis symptoms. The pharmacological data and the experience accumulated with cisapride suggest that it is a safe drug which can be prescribed without any other precaution than those given concerning any new medication; cisapride has also proved satisfactory and safe in children. 27 If the present findings can be confirmed, cisapride will prove to be a valuable adjunct to cimetidine in the treatment of severe reflux oesophagitis.
